



Published in final edited form as:

Metabolism. 2014 June ; 63(6): 773–782. doi:10.1016/j.metabol.2014.03.008.

Circulating alanine transaminase (ALT) and γ -glutamyl transferase (GGT), but not fetuin-A, is associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus Metabolism Study

Xiaowen Liu, PhD¹, Ole-Petter R Hamnvik, MD², John P Chamberland, BS^{1,5}, Michael Petrou, MD³, Huizhi Gong, MD¹, Costas A Christophi, PhD^{3,4}, David C Christiani, MD, MPH⁴, Stefanos N Kales, MD, MPH⁴, and Christos S Mantzoros, MD^{1,2,4,5}

¹Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

²Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

³Cyprus International Institute for Environmental and Public Health in association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus

⁴Department of Environmental Health, Harvard School of Public Health, Boston, MA

⁵Section of Endocrinology, Boston VA Healthcare System, Boston, MA

Abstract

Objective—To comparatively evaluate traditional liver tests and fetuin A as predictors of cardiometabolic risk, we studied associations between serum alanine transaminase (ALT), γ -glutamyl transferase (GGT), aspartate aminotransferase (AST) and fetuin-A and anthropometric, metabolic, and cardiovascular parameters cross-sectionally at baseline, and prospectively, after 2-years of follow-up.

© 2014 Elsevier Inc. All rights reserved.

Corresponding author: Stefanos N Kales, Department of Environmental Health, Harvard School of Public Health, Cambridge Hospital, Maeth Building 427, 1493 Cambridge St., Cambridge, MA 02139. Telephone number: 617-665-1580. Fax number: 617-665-1672. skales@hsph.harvard.edu.

Disclosure statement: The authors have nothing to disclose.

Author contributions

CSM derived the hypothesis and conceived the study design; MP, CAC, SNK, and DCC planned and organized the collection of the data; XL, HG, and JPC performed the laboratory analyses; XL and CSM planned and did the statistical analyses and XL collated the data and run the statistical analyses, XL, OPRH, MP, CAC, SNK, DCC, and CSM contributed to the interpretation and discussion of results; XL, OPRH wrote initial versions of the manuscript and CSM completed the manuscript. This report was critically reviewed and subsequently approved by all authors.

Disclosure

The authors have no relevant conflict of interests.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Research Design and Methods—616 randomly enrolled young healthy participants in the Cyprus Metabolism Study, including all 93 subjects who participated in the follow-up study 2 years after baseline assessment, were included in this study.

Results—In the cross-sectional study, serum ALT and GGT were strongly correlated with anthropometric, cardiovascular, and metabolic variables, while serum AST was only correlated with waist circumference and waist-to-hip ratio. Fetuin-A was correlated with anthropometric variables, systolic blood pressure (SBP), insulin, and homeostasis model of assessment-insulin resistance (HOMA-IR) in the unadjusted model. In the fully adjusted model, both serum ALT and GGT levels remained positively correlated with total and low-density lipoprotein (LDL) cholesterol. GGT levels also remained correlated with triglycerides. ALT levels remained strongly positively correlated with insulin ($r=0.17$, $p<.0001$) and HOMA-IR ($r=0.16$, $p=0.0001$). Serum fetuin-A levels were no longer significantly correlated with any variables. Prospectively, ALT and GGT were predictors of anthropometric variables and LDL cholesterol, while baseline levels of AST and fetuin-A were not predictors of any variables at 2-year follow-up.

Conclusions—We confirmed associations of ALT and GGT levels but failed to demonstrate an independent association between fetuin-A and cardiometabolic risk factors in young healthy men. Traditional liver tests (LFTs) are thus better than fetuin-A predictors of metabolic risk factors cross-sectionally and prospectively in young healthy adults.

Keywords

obesity; insulin resistance; metabolic syndrome

Introduction

Obesity is a risk factor for the development of insulin resistance, hypertension and dyslipidemia, which increase an individual's eventual risk of developing type 2 diabetes mellitus and cardiovascular disease [1–3]. The mechanisms underlying these adverse metabolic effects of obesity have been the subject of intense investigation. The clustering of disturbed glucose and insulin metabolism, overweight and abdominal fat distribution, hypertension, and dyslipidemia, i.e. the metabolic syndrome, has also been associated with non-alcoholic fatty liver disease (NAFLD) [4, 5] [6]. Similar to NAFLD, abnormal liver function tests are considered markers of the metabolic syndrome and may be stronger predictors of a worse metabolic milieu than other clinical measurements [7, 8] [9].

Alanine transaminase (ALT) is a widely used serum marker of liver disease and even a minor elevation of ALT is a good predictor of mortality from liver disease [10, 11]. γ -glutamyltransferase (GGT) and aspartate aminotransferase (AST) are mainly derived from the liver and hence often considered liver function tests (LFTs), although a significant contribution from other tissues makes them imperfect markers of liver function alone. Recently, a number of observational studies have suggested that abnormal LFTs are associated with obesity, insulin resistance, and metabolic syndromes [4, 12–14]. Several prospective studies have also shown that high levels of ALT and GGT are independently associated with increased risk for incident metabolic syndrome and diabetes [12, 15–19]. In non-diabetic subjects, some studies suggested that GGT might be a stronger predictor of

development of type 2 diabetes than AST or ALT [19–21] while others have suggested that ALT is the only predictor [12]. All prior studies have been focused on middle to old-aged populations and thus data on young adults are lacking.

Fetuin-A, also known as alpha-2-Heremans-Schmid glycoprotein, is another serum protein that is mostly derived from liver, with limited contribution from the tongue and placenta [22]. Fetuin-A has attracted much attention since recent cross-sectional human studies have found that levels of fetuin-A are associated with insulin resistance [23, 24], metabolic syndrome [25, 26], visceral adipose tissue [27], fatty liver, body mass index (BMI), waist circumference, and an atherogenic lipid profile. Weight loss induced by bariatric surgery has also been shown to lead to a decrease in fetuin-A levels [28]. In prospective studies, even after adjusting for markers of body composition, increased levels of fetuin-A have been linked to increased amount of visceral adipose tissue at five-years of follow-up in a group of 508 older subjects [29], as well as increased incidence of type 2 diabetes mellitus in both older and middle-aged subjects [27, 30]. Prospective studies have also found a higher risk of clinical manifestations of atherosclerotic disease with elevated fetuin-A levels, including myocardial infarction and stroke, potentially through its association with insulin resistance and associated adverse metabolic findings [31, 32].

No study to date has studied associations between fetuin-A, anthropometrics and metabolic risk factors in young adults. Moreover, no prior studies have comparatively assessed fetuin-A and traditional LFTs as predictors of cardiovascular and metabolic disease in either young or older individuals.

Thus, we investigated fetuin-A as a marker of cardiovascular and metabolic risk factors in a population of young men, both cross-sectionally and prospectively. We then comparatively evaluated traditional liver enzymes ALT, AST and GGT vs. fetuin-A as predictors of cardiovascular and metabolic diseases.

Materials and Methods

Subjects

The full design of the Cyprus Metabolism Study has been published elsewhere [33, 34] [34]. This research has received institutional approval from both Harvard School of Public Health and the Cyprus National Bioethics Committee.

Cross-sectional study—In brief, 1056 eighteen-year-old candidates for recruitment in the Cypriot Army were enrolled in the study in July 2006 and 2007. For this study, a random subgroup of 616 participants was studied.

Prospective study—All participants who enrolled in the study in July 2006 were contacted for the two-year follow-up study. One hundred and fifteen out of 417 eligible study participants expressed an interest in participating and could make the appointment to be seen at the Nicosia General Hospital for the follow-up evaluation two years later in July 2008. Twenty-one participants were excluded because of lack of a baseline sample for fetuin-A assays. One other participant was excluded because no follow-up weight was

available. This resulted in 93 participants eligible for inclusion in the prospective analyses. No major differences were detected between the initial group of subjects and the 93 participants in the prospective analysis [34].

Measurements

Baseline and follow-up anthropometric and metabolic measures were ascertained using standardized methods [33, 34]. Body composition was measured using the TanitaTBF-300A Body Composition Analyzer; basal metabolic rate was calculated by the analyzer using a Tanita proprietary formula. Activity level was assessed using questionnaires and includes both exercise and habitual activities such as walking or farm work. Baseline liver function tests including albumin, ALT, AST, alkaline phosphatase, total bilirubin, and GGT were assessed at Nicosia General Hospital using routine automated laboratory methods (Olympus AU270™ Chemistry-Immuno Analyzer, Olympus, Center Valley, PA). De-identified frozen samples were shipped to Beth Israel Deaconess Medical Center and serum fetuin-A levels were measured using sandwich enzyme immunoassay (ELISA, BioVendor, Candler, NC). All samples were analyzed in duplicate in the same assay. Assay sensitivities as well as interassay and intraassay coefficients of variation were similar to those reported by the manufacturer.

Statistical analysis

All the variables were tested for normal distribution and logarithmically transformed if not normally distributed. Results were presented as mean values \pm S.E.M., or for categorical variables, number and percentage, were used for the descriptive statistics. SAS (version 9.1, SAS Institute, Cary, NC) was used for statistical analysis. $P < 0.0125$ was considered statistically significant based on Bonferroni correction testing four dependent or independent hypotheses at the same time on one set of data.

Baseline characteristics of the follow-up group were compared to those of the entire cohort using t-test for continuous variables and chi-square test for categorical variables. Characteristics of participants at baseline and at follow-up were compared by repeated measures analysis of variance for both continuous and categorical variables.

Pearson correlation coefficients and the probabilities associated with this statistic were obtained between variables in the cross-sectional study. Pearson partial correlation coefficients were obtained after controlling for the effects of age, smoking status, activity, BMI, body fat percentage, and waist-to-hip ratio (WHR) between variables. General linear models and logistic regression analysis were used in the prospective study. The area under the receiver operating characteristic (ROC) curves was used to compare accuracy of logistic regression models.

Results

Cross-sectional study

Descriptive characteristics of the study population are presented in Table 1. As expected from a young healthy population, all mean values were within the normal range. However,

29.5% of the participants had a BMI greater than 25 kg/m². Dyslipidemia was found in 30.0% of the participants, mainly due to elevated low-density lipoprotein (LDL) or low high-density lipoprotein (HDL) cholesterol.

Findings from the cross-sectional portion of the study are summarized in Table 2. In the unadjusted model, we found that serum ALT and GGT levels were strongly positively correlated with anthropometric, cardiovascular, and metabolic variables, except for height, HDL cholesterol, urea and creatinine. On the other hand, AST levels were only correlated with waist circumference and WHR. Serum fetuin-A levels were significantly positively correlated with most anthropometric variables including body weight ($r=0.15$, $p=0.0002$), BMI ($r=0.15$, $p=0.0004$), total body fat ($r=0.14$, $p=0.0009$), body fat mass ($r=0.13$, $p=0.001$), body fat-free mass ($r=0.15$, $p=0.0003$), waist ($r=0.16$, $p<0.0001$) and hip circumferences ($r=0.16$, $p<0.0001$), WHR ($r=0.11$, $p=0.010$), and BMR ($r=0.15$, $p=0.0003$). Serum fetuin-A levels were also significantly correlated with some cardiovascular and metabolic variables, such as systolic blood pressure (SBP, $r=0.12$, $p=0.004$), insulin ($r=0.15$, $p=0.0002$), homeostasis model of assessment-insulin resistance (HOMA-IR, $r=0.14$, $p=0.0005$), and leptin ($r=0.10$, $p=0.012$).

After controlling for the effects of age, smoking status, activity, BMI, body fat percentage, and WHR, serum ALT and GGT levels remained strongly positively correlated with total and LDL cholesterol. ALT levels also remained strongly positively correlated with heart rate ($r=0.14$, $p=0.0003$), insulin ($r=0.17$, $p<0.0001$) and HOMA-IR ($r=0.16$, $p=0.0001$), and serum GGT levels remained positively correlated with triglycerides and leptin. In the fully adjusted model, serum AST and fetuin-A levels were not significantly correlated with any cardiovascular and metabolic variables.

In multi-variable linear regression analysis including ALT, GGT, AST and fetuin-A as dependent variables, ALT has the strongest association with anthropometric variables, cardiovascular risk factors (except for DBP, HDL cholesterol and triglycerides), leptin, uric acid, urea, insulin, and HOMA-IR. GGT has strongest association with triglycerides and LBP. GGT also showed less strong association with anthropometric variables, cardiovascular risk factors, and leptin. AST has much less strong association with anthropometric variables, insulin, HOMA-IR and no association with cardiovascular variables in these models. Fetuin-A does not have any significant association with any variables in these models. After controlling for age, smoking status, activity, BMI, body fat percentage, and WHR, only serum ALT levels are independently strongly associated with insulin, HOMA-IR, and heart rate. Both serum GGT and ALT levels are independently associated with total, and LDL cholesterol. AST and fetuin-A are no longer associated with any variables in the adjusted model.

Prospective study

Table 3 shows the baseline and follow-up characteristics of the 93 participants who took part in the prospective study. Interestingly, most of the anthropometric variables and cardiovascular risk factors significantly worsened over the 2-year period between visits.

Findings from the prospective portion of the study are summarized in Table 4. In the unadjusted model, baseline serum ALT and GGT levels were significant predictors of BMI, body weight, total body fat, body fat mass, waist circumference, hip circumference, WHR, body fat-free mass, BMR, and LDL cholesterol at 2-years of follow-up (for ALT, $p=0.0004-0.01$, $\beta=0.27-0.37$; for GGT, $p<0.0001-0.003$, $\beta=0.32-0.52$). In the models adjusted for baseline age, smoking status, activity, BMI, body fat percentage, and WHR, the baseline serum GGT level remained a significant predictor of LDL cholesterol ($p=0.003$, $\beta=0.32$), whereas serum ALT was not predictive of any cardiovascular or metabolic variable. Unlike ALT and GGT, baseline serum AST levels were not predictive of any anthropometric, cardiovascular, and metabolic variables in either unadjusted or adjusted models.

Similarly, the changes of serum ALT and GGT levels from baseline to 2-year follow-up were strong predictors of changes of all anthropometric variables in the unadjusted model. The change of serum ALT levels was also a significant predictor of change of triglycerides ($p=0.005$, $\beta=0.28$), and the change of serum GGT levels was also a significant predictor of change of total ($p<0.0001$, $\beta=0.41$), HDL ($p=0.002$, $\beta=0.31$) and LDL ($p=0.01$, $\beta=0.26$) cholesterol in unadjusted models. In the model adjusted for baseline age, smoking status, activity, BMI, body fat percentage, and WHR, the change of serum GGT levels remained significantly associated with the change of total ($p<0.0001$, $\beta=0.41$), HDL ($p=0.002$, $\beta=0.33$) and LDL ($p=0.01$, $\beta=0.26$) cholesterol while the change of serum ALT levels were only significantly associated with HDL cholesterol ($p=0.008$, $\beta=0.31$).

Baseline levels of serum fetuin-A were not a significant predictor of any anthropometrics, cardiovascular, and metabolic variables at two-year follow-up in either unadjusted or adjusted models.

Using logistic regression analysis, serum ALT has fair accuracy to significantly predict a total cholesterol level of >200 mg/dL vs. <200 mg/dL, as measured using the area under the ROC curve method (ROC AUC =0.67, $p=0.02$, and/or OR = 0.949 [0.909, 0.992]) indicating that each 1 U/L decrease of ALT conveys an approximately 5% lower probability of having total cholesterol >200 mg/dL. Serum AST and fetuin-A levels were not significant predictors of categorically analyzed cholesterol levels.

Discussion

In this study, we demonstrated that the liver-derived enzymes ALT and GGT are strongly positively correlated to BMI, adiposity, fat free mass, BMR, blood pressure, total and LDL cholesterol, triglycerides, dyslipidemia, fasting glucose, insulin, and HOMA-IR in young healthy adults. In addition, after adjusting for various confounders, ALT remained associated with heart rate, total and LDL cholesterol, insulin, and HOMA-IR, suggesting that these correlations are independent from any underlying correlation with body composition, age, smoking status, and activity level. Conversely, GGT predicts only LDL cholesterol whereas ALT predicts no parameters at two-year follow-up in the adjusted models. Similarly, when compared to ALT and GGT, we found that fetuin-A was less strongly associated with anthropometric parameters, SBP, insulin, HOMA-IR, and leptin. In

addition, we showed for the first time, that fetuin-A is not an independent predictor of metabolic risk factors in young healthy men since these correlations became nonsignificant in this group of lean insulin-sensitive 18-year-old subjects after adjusting for various confounders. This suggests that fetuin-A is not as closely correlated to these parameters when compared with traditional LFTs and that to a large extent, its associations with cardiometabolic risk factors may be due to an underlying correlation with body composition.

Our data are in agreement with prior cross-sectional studies of mostly middle-aged participants, linking ALT and GGT to components of the metabolic syndrome, as well as type 2 diabetes mellitus [4, 9, 12, 35]. For example, in a large population-based study analyzing data from the Third National Health and Nutrition Examination Survey (NHANES III), ALT elevation was associated with a number of risk factors of NAFLD, such as impaired glucose metabolism, insulin resistance, central obesity, high leptin and triglycerides, even when patients with known diabetes (who are at high risk for NAFLD) were excluded [36]. Others have found similar cross-sectional correlations between GGT and components of the metabolic syndrome [37]. Both GGT and ALT have also been shown prospectively to predict the development of insulin resistance and diabetes mellitus [12, 15, 17, 38, 39], which we did not find in this population of healthy 18-year-old men.

In the present study, we found that fetuin-A was significantly correlated with body fat distribution, but not with insulin resistance in young healthy men. Similar to our findings, prior studies in middle-aged or older populations have found that fetuin-A is correlated with truncal obesity [40]. However, many studies have reported a significant correlation between fetuin-A and impaired fasting glucose [41, 42], metabolic syndrome [43], insulin resistance [24], type 2 diabetes [42, 44–46] and prospective studies have found that fetuin-A has an independent association with type 2 diabetes mellitus [27, 30] in middle-aged or old overweight populations. Interestingly, Jenkins *et al* found that there was no significant relationship between plasma fetuin-A and insulin or HOMA-IR in the combined groups of older individuals and young participants in their study. However, plasma fetuin-A levels trended to be correlated with insulin and HOMA-IR in older but not in younger participants, suggesting effect modification by age [47]. We also found that fetuin-A is not an independent predictor of metabolic risk factors or dyslipidemia in our younger cohort. It has been shown that higher fetuin-A levels are associated with visceral adipose tissue (VAT) as opposed to overall body fat [29]. Deposition of VAT may play a more important role with advancing age and increasing BMI, explaining the negative result in this young healthy cohort. Jenkins *et al* found in their younger participants that plasma fetuin-A was significantly related to blood pressure and blood lipid variables; in our study, fetuin-A was associated with SBP but no other blood pressure or lipid variables at baseline.

In summary, the novel findings of our study are that fetuin-A levels are not independently associated with any metabolic or cardiovascular risk factor at baseline and are not a better than traditional LFTs predictor of these variables cross-sectionally and prospectively in young adults.

The strengths of this study are that it is the first cross-sectional and prospective study comparing associations between serum liver enzymes, serum fetuin-A levels and

cardiovascular and metabolic characteristics in young men. We also adjusted for known potential confounders, such as smoking status and activity in our analysis, thus eliminating bias or confounding by these variables. Measurements were performed under code using de-identified specimens and state of the art methodology by technicians who were blinded to the study hypotheses eliminating bias from these sources. Random assay variability could have resulted in misclassification but this random misclassification would have suppressed effect estimates and hence is should not have resulted in statistical significance where this does not exist.

The limitations of our study include the relatively short follow-up time of only 2 years; this period of time has been shown to be adequate in terms of evaluation of cardiometabolic predictors of risk in prior studies and in this study in terms of traditional LFTs. Despite the large number of subjects in the cross sectional study, the prospective study included only a relatively small follow-up group (93 subjects) but numbers of subjects were sufficient to demonstrate significant associations between serum liver enzymes levels and outcomes of interest. The results may not be directly generalizable to other populations since we focused on a young and healthy population of Mediterranean decent. Future prospective studies are needed to confirm our data in cohorts of women and/or older subjects in the same and other ethnic groups. Moreover, interventional, mechanistic studies are needed to interpret our findings that fetuin-A may not be a better indicator of the metabolic syndrome, diabetes, and cardiovascular disease compared to traditional LFTs in younger adults as this study clearly demonstrates.

Acknowledgments

Grants: The study was supported by the Cyprus Research Promotion Foundation (EPYEE/0205/10). The Mantzoros Lab is supported by grants DK58785, DK79929, DK81913, AG032030, a VA Merit award and a discretionary grant from Beth Israel Deaconess Medical Center. This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (NIH Award #UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic health care centers).

We would like to thank the Harvard Cyprus Program, Nicosia General Hospital, all volunteers for participating in the study, and especially Maria Michael, Androula Chasikou-Constantinidou, and Christos Tapakoudes for their expert technical assistance.

List of abbreviations

ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
AUC	Area under the curve
BMI	Body mass index
BMR	Basal metabolic rate
BP	Blood pressure
DBP	Diastolic blood pressure
ELISA	Enzyme-linked immunosorbent assay

GGT	Gamma-glutamyl transferase
HDL	High-density lipoprotein
HOMA-IR	Homeostasis model of assessment of insulin resistance
hsCRP	High sensitivity C-reactive protein
IDF	International Diabetes Federation
LDL	Low-density lipoprotein
LBP	Leptin-binding protein
LFTs	Liver function tests
NAFLD	Non-alcoholic fatty liver disease
NGAL	Neutrophil gelatinase-associated lipocalin
NHANES III	Third National Health and Nutrition Examination Survey
ROC	Receiver operating characteristic
SBP	Systolic blood pressure
SE	Standard error
VAT	Visceral adipose tissue
WHR	Waist-to-hip ratio

References

1. Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia. *Obes Res.* 2000; 8(9):605–19. [PubMed: 11225709]
2. Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women. *Am J Epidemiol.* 1990; 132(3):501–13. [PubMed: 2389754]
3. Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: The framingham experience. *Arch Intern Med.* 2002; 162(16):1867–72. [PubMed: 12196085]
4. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. *Diabetes.* 2001; 50(8):1844–50. [PubMed: 11473047]
5. Marchesini G, Avagnina S, Barantani EG, et al. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. *J Endocrinol Invest.* 2005; 28(4):333–9. [PubMed: 15966506]
6. Younossi ZM, Otgonsuren M, Venkatesan C, et al. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. *Metabolism.* 2013; 62(3):352–60. [PubMed: 22999011]
7. Devers MC, Campbell S, Shaw J, et al. Should liver function tests be included in definitions of metabolic syndrome? Evidence from the association between liver function tests, components of metabolic syndrome and prevalent cardiovascular disease. *Diabet Med.* 2008; 25(5):523–9. [PubMed: 18346165]
8. Hsieh MH, Ho CK, Hou NJ, et al. Abnormal liver function test results are related to metabolic syndrome and bmi in taiwanese adults without chronic hepatitis b or c. *Int J Obes (Lond).* 2009; 33(11):1309–17. [PubMed: 19752878]

9. Hong HC, Lee JS, Choi HY, et al. Liver enzymes and vitamin d levels in metabolically healthy but obese individuals: Korean national health and nutrition examination survey. *Metabolism*. 2013; 62(9):1305–12. [PubMed: 23643404]
10. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study. *BMJ*. 2004; 328(7446):983. [PubMed: 15028636]
11. West J, Brousil J, Gazis A, et al. Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus. *QJM*. 2006; 99(12):871–6. [PubMed: 17121768]
12. Vojarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. *Diabetes*. 2002; 51(6):1889–95. [PubMed: 12031978]
13. Kasapoglu B, Turkay C, Bayram Y, et al. Role of ggt in diagnosis of metabolic syndrome: A clinic-based cross-sectional survey. *Indian J Med Res*. 2010; 132:56–61. [PubMed: 20693590]
14. Messier V, Karelis AD, Robillard ME, et al. Metabolically healthy but obese individuals: Relationship with hepatic enzymes. *Metabolism*. 2010; 59(1):20–4. [PubMed: 19709695]
15. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of niddm. *Diabetes Care*. 1998; 21(5):732–7. [PubMed: 9589232]
16. Andre P, Balkau B, Born C, et al. Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: The d.E.S.I.R. Cohort. *Diabetologia*. 2006; 49(11):2599–603. [PubMed: 16969645]
17. Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: The insulin resistance atherosclerosis study. *Diabetes*. 2004; 53(10):2623–32. [PubMed: 15448093]
18. Lee DH, Silventoinen K, Jacobs DR Jr, et al. Gamma-glutamyltransferase, obesity, and the risk of type 2 diabetes: Observational cohort study among 20,158 middle-aged men and women. *J Clin Endocrinol Metab*. 2004; 89(11):5410–4. [PubMed: 15531490]
19. Jo SK, Lee WY, Rhee EJ, et al. Serum gamma-glutamyl transferase activity predicts future development of metabolic syndrome defined by 2 different criteria. *Clin Chim Acta*. 2009; 403(1–2):234–40. [PubMed: 19332046]
20. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged japanese men. *Diabetes Care*. 2004; 27(6):1427–32. [PubMed: 15161799]
21. Andre P, Balkau B, Born C, et al. Hepatic markers and development of type 2 diabetes in middle aged men and women: A three-year follow-up study. The d.E.S.I.R. Study (data from an epidemiological study on the insulin resistance syndrome). *Diabetes Metab*. 2005; 31(6):542–50. [PubMed: 16357802]
22. Denecke B, Graber S, Schafer C, et al. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-b and fetuin-a. *Biochem J*. 2003; 376(Pt 1):135–45. [PubMed: 12943536]
23. Mori K, Emoto M, Yokoyama H, et al. Association of serum fetuin-a with insulin resistance in type 2 diabetic and nondiabetic subjects. *Diabetes Care*. 2006; 29(2):468. [PubMed: 16443916]
24. Ishibashi A, Ikeda Y, Ohguro T, et al. Serum fetuin-a is an independent marker of insulin resistance in japanese men. *J Atheroscler Thromb*. 17(9):925–33. [PubMed: 20543523]
25. Stefan N, Hennige AM, Staiger H, et al. Alpha2-heremans-schmid glycoprotein/fetuin-a is associated with insulin resistance and fat accumulation in the liver in humans. *Diabetes Care*. 2006; 29(4):853–7. [PubMed: 16567827]
26. Ix JH, Shlipak MG, Brandenburg VM, et al. Association between human fetuin-a and the metabolic syndrome: Data from the heart and soul study. *Circulation*. 2006; 113(14):1760–7. [PubMed: 16567568]
27. Ix JH, Wassel CL, Kanaya AM, et al. Fetuin-a and incident diabetes mellitus in older persons. *JAMA*. 2008; 300(2):182–8. [PubMed: 18612115]
28. Brix JM, Stingl H, Hollerl F, et al. Elevated fetuin-a concentrations in morbid obesity decrease after dramatic weight loss. *J Clin Endocrinol Metab*. 2010; 95(11):4877–81. [PubMed: 20660040]

29. Ix JH, Wassel CL, Chertow GM, et al. Fetuin-a and change in body composition in older persons. *J Clin Endocrinol Metab.* 2009; 94(11):4492–8. [PubMed: 19820014]
30. Stefan N, Fritsche A, Weikert C, et al. Plasma fetuin-a levels and the risk of type 2 diabetes. *Diabetes.* 2008; 57(10):2762–7. [PubMed: 18633113]
31. Weikert C, Stefan N, Schulze MB, et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. *Circulation.* 2008; 118(24):2555–62. [PubMed: 19029462]
32. Fisher E, Stefan N, Saar K, et al. Association of ahsg gene polymorphisms with fetuin-a plasma levels and cardiovascular diseases in the epic-potsdam study. *Circ Cardiovasc Genet.* 2009; 2(6): 607–13. [PubMed: 20031641]
33. Hamnvik OP, Liu X, Petrou M, et al. Soluble leptin receptor and leptin are associated with baseline adiposity and metabolic risk factors, and predict adiposity, metabolic syndrome, and glucose levels at 2-year follow-up: The cyprus metabolism prospective cohort study. *Metabolism.* 2011; 60(7): 987–93. [PubMed: 21056886]
34. Liu X, Hamnvik OP, Petrou M, et al. Circulating lipocalin 2 is associated with body fat distribution at baseline but is not an independent predictor of insulin resistance: The prospective cyprus metabolism study. *Eur J Endocrinol.* 2011; 165(5):805–12. [PubMed: 21885675]
35. Zhang Y, Lu X, Hong J, et al. Positive correlations of liver enzymes with metabolic syndrome including insulin resistance in newly diagnosed type 2 diabetes mellitus. *Endocrine.* 38(2):181–7. [PubMed: 20972737]
36. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the united states. *Gastroenterology.* 2003; 124(1):71–9. [PubMed: 12512031]
37. Wallace TM, Utzschneider KM, Tong J, et al. Relationship of liver enzymes to insulin sensitivity and intra-abdominal fat. *Diabetes Care.* 2007; 30(10):2673–8. [PubMed: 17666458]
38. Thamer C, Tschritter O, Haap M, et al. Elevated serum ggt concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. *Horm Metab Res.* 2005; 37(4):246–51. [PubMed: 15952086]
39. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. *J Clin Endocrinol Metab.* 2011; 96(4):1093–7. [PubMed: 21252243]
40. Chen HY, Chiu YL, Hsu SP, et al. Association of serum fetuin a with truncal obesity and dyslipidemia in non-diabetic hemodialysis patients. *Eur J Endocrinol.* 2009; 160(5):777–83. [PubMed: 19228823]
41. Tonjes A, Fasshauer M, Kratzsch J, et al. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. *PLoS One.* 2010; 5(11):e13911. [PubMed: 21085476]
42. Ou HY, Yang YC, Wu HT, et al. Serum fetuin-a concentrations are elevated in subjects with impaired glucose tolerance and newly-diagnosed type 2 diabetes. *Clin Endocrinol (Oxf).* 2011
43. Xu Y, Xu M, Bi Y, et al. Serum fetuin-a is correlated with metabolic syndrome in middle-aged and elderly chinese. *Atherosclerosis.* 2011; 216(1):180–6. [PubMed: 21310413]
44. Song A, Xu M, Bi Y, et al. Serum fetuin-a associates with type 2 diabetes and insulin resistance in chinese adults. *PLoS One.* 2011; 6(4):e19228. [PubMed: 21556362]
45. Lorant DP, Grujicic M, Hoebaus C, et al. Fetuin-a levels are increased in patients with type 2 diabetes and peripheral arterial disease. *Diabetes Care.* 2011; 34(1):156–61. [PubMed: 20929991]
46. Roos M, Oikonomou D, von Eynatten M, et al. Associations of fetuin-a levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. *Cardiovasc Diabetol.* 2010; 9:48. [PubMed: 20822519]
47. Jenkins NT, McKenzie JA, Hagberg JM, et al. Plasma fetuin-a concentrations in young and older high- and low-active men. *Metabolism.* 2011; 60(2):265–71. [PubMed: 20199782]

Table 1

Baseline characteristics of participants in the cross-sectional study.

Variables	All subjects (n = 616)
Age (yr)	18.3±0.02
Activity (hr/week)	11.6±0.5
Anthropometric variables	
Height (cm)	175.0±0.2
Weight (kg)	72.6±0.6
BMI (kg/m ²)	23.7±0.2
Total body fat (%)	14.2±0.3
Fat mass (kg)	11.2±0.3
Fat-free mass (kg)	61.5±0.3
Waist circumference (cm)	82.0±0.4
Hip circumference (cm)	97.3±0.4
Waist-to-hip ratio	0.84±0.002
BMR (kcal/day)	1822±9
Cardiovascular risk factors	
Heart rate (beats/min)	69.8±0.4
SBP (mmHg)	108.1±0.4
DBP (mmHg)	63.8±0.3
Total cholesterol (mg/dL)	154.8±1.3
HDL cholesterol (mg/dL)	48.1±0.4
LDL cholesterol (mg/dL)	103.8±1.1
Triglycerides (mg/dL)	60.4±1.0
Fasting glucose (mg/dL)	81.6±0.3
Insulin (ng/mL)	9.1±0.2
HOMA-IR	1.88±0.05
Leptin (ng/mL)	2.55±0.11
LBP (ng/mL)	23.4±0.2
Fetuin-A (ug/mL)	295.5±2.8
Uric Acid (ng/dL)	6.7±0.1
Urea (ng/dL)	35.6±0.3
Creatinine (ng/dL)	1.0±0.004
Liver Function test	
GGT (U/L)	25.2±0.6
ALT (U/L)	27.7±0.9
AST (U/L)	27.8±1.1
Categorical variables	
Smoking status	
<i>Never</i>	368 (59.7)
<i>Previous</i>	26 (4.2)
<i>Current</i>	222 (36.1)

Variables	All subjects (n = 616)
BMI >25 kg/m ²	182 (29.5)
Waist circumference >94 cm	96 (15.6)
Total cholesterol >200 mg/dL	48 (7.9)
HDL <40 mg/dL	103 (16.9)
LDL >130 mg/dL	94 (15.4)
Dyslipidemia	183 (30.0)

Results are presented as mean±SEM, or as n(%).

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BMR, basal metabolic rate; DBP, Diastolic blood pressure; GGT, gamma-glutamyl transferase; HDL, High-density lipoprotein; HOMA-IR, homeostasis model of assessment-insulin resistance; LBP, leptin-binding protein; LDL, Low-density lipoprotein; SBP, Systolic blood pressure; SE, standard error.

Table 2

Correlations between liver function tests, fetuin-A and baseline values of study variables

	ALT				GGT				AST				Fetuin-A					
	Model 1		Model 2		Model 1		Model 2		Model 1		Model 2		Model 1		Model 2			
	r	P	r	P	r	P	r	P	r	P	r	P	r	P	r	P		
Age	0.01	0.74	-0.02	0.61	0.11	0.01	-0.04	0.31	0.11	0.01	0.11	0.01	-0.04	0.31	0.11	0.01		
Activity	-0.02	0.67	-0.03	0.44	-0.03	0.47	-0.03	0.47	-0.03	0.47	-0.03	0.47	0.02	0.70	0.02	0.70		
Smoking status	0.06	0.16	0.13	0.001	0.02	0.58	0.02	0.58	0.02	0.58	0.02	0.58	-0.03	0.53	-0.03	0.53		
Anthropometrics																		
Height	0.06	0.12	-0.04	0.34	0.02	0.70	0.02	0.70	0.02	0.70	0.02	0.70	0.05	0.22	0.05	0.22		
Weight	0.44	< 0.001	0.39	< 0.001	0.09	0.02	0.09	0.02	0.09	0.02	0.09	0.02	0.15	0.0002	0.15	0.0002		
BMI	0.46	< 0.001	0.45	< 0.001	0.10	0.02	0.10	0.02	0.10	0.02	0.10	0.02	0.15	0.0004	0.15	0.0004		
Total body fat	0.46	< 0.001	0.46	< 0.001	0.10	0.01	0.10	0.01	0.10	0.01	0.10	0.01	0.14	0.0009	0.14	0.0009		
Fat mass	0.47	< 0.001	0.44	< 0.001	0.10	0.01	0.10	0.01	0.10	0.01	0.10	0.01	0.13	0.001	0.13	0.001		
Fat free mass	0.36	< 0.001	0.30	< 0.001	-0.08	0.06	0.08	0.06	0.08	0.06	0.08	0.06	0.15	0.0003	0.15	0.0003		
Waist circumference	0.47	< 0.001	0.45	< 0.001	0.11	0.006	0.11	0.006	0.11	0.006	0.11	0.006	0.16	< 0.0001	0.16	< 0.0001		
Hip circumference	0.41	< 0.001	0.39	< 0.001	0.18	0.06	0.18	0.06	0.18	0.06	0.18	0.06	0.16	< 0.0001	0.16	< 0.0001		
WHR	0.39	< 0.001	0.40	< 0.001	0.13	0.001	0.13	0.001	0.13	0.001	0.13	0.001	0.11	0.010	0.11	0.010		
BMR	0.42	< 0.001	0.36	< 0.001	0.09	0.03	0.09	0.03	0.09	0.03	0.09	0.03	0.15	0.0003	0.15	0.0003		
Cardiovascular risk factors																		
Heart rate	0.22	< 0.001	0.14	0.0003	0.06	0.13	0.06	0.13	0.06	0.13	0.06	0.13	0.01	0.75	0.04	0.39	0.01	0.73
SBP	0.31	< 0.001	0.10	0.015	0.08	0.06	0.08	0.06	0.05	0.21	0.003	0.95	0.12	0.004	0.12	0.004	0.04	0.30
DBP	0.14	0.0004	-0.001	0.97	-0.01	0.76	0.03	0.47	0.03	0.47	-0.01	0.81	0.07	0.08	0.07	0.08	0.03	0.54
Total cholesterol	0.32	< 0.001	0.19	< 0.001	0.24	< 0.001	0.35	< 0.001	0.08	0.04	0.04	0.32	0.06	0.12	0.06	0.12	0.03	0.40
HDL	-0.03	0.50	0.08	0.04	-0.07	0.07	-0.07	0.07	0.01	0.74	0.04	0.28	-0.02	0.71	-0.02	0.71	0.02	0.61
LDL	0.34	< 0.001	0.21	< 0.001	0.26	< 0.001	0.38	< 0.001	0.07	0.06	0.04	0.38	0.10	0.02	0.10	0.02	0.07	0.11
Triglycerides	0.19	< 0.001	-0.002	0.95	0.31	< 0.001	0.13	0.001	-0.01	0.76	-0.06	0.13	0.04	0.28	0.04	0.28	-0.005	0.91
Dyslipidemia	0.18	< 0.001	0.05	0.18	0.17	< 0.001	0.04	0.33	0.02	0.70	-0.01	0.74	0.01	0.74	0.01	0.74	-0.02	0.62
Hormonal and metabolic variables																		
Fasting glucose	0.13	0.001	0.01	0.77	0.14	0.0003	0.04	0.30	0.02	0.60	-0.003	0.93	0.01	0.74	0.01	0.74	-0.03	0.53
Insulin	0.37	< 0.001	0.17	< 0.001	0.09	0.02	0.07	0.09	0.02	0.62	0.02	0.62	0.15	0.0002	0.15	0.0002	0.08	0.07

	ALT						GGT						AST						Fetuin-A					
	Model 1		Model 2		Model 1		Model 2		Model 1		Model 2		Model 1		Model 2		Model 1		Model 2					
	r	P	r	P	r	P	r	P	r	P	r	P	r	P	r	P	r	P	r	P				
HOMA-IR	0.36	<0.0001	0.16	0.0001	0.30	<0.0001	0.09	0.02	0.07	0.10	0.02	0.63	0.14	0.0005	0.06	0.12								
Leptin*	0.41	<0.0001	0.04	0.31	0.46	<0.0001	0.15	0.0002	0.07	0.09	-0.03	0.43	0.10	0.012	-0.02	0.54								
LBP	-0.16	<0.0001	0.06	0.14	-0.21	<0.0001	-0.02	0.97	-0.02	0.56	0.03	0.48	-0.08	0.06	-0.01	0.88								
Uric acid	0.13	0.001	0.05	0.26	0.14	0.0003	0.06	0.14	0.06	0.13	0.04	0.27	0.02	0.56	0.001	0.99								
Urea	-0.02	0.60	0.02	0.59	-0.04	0.35	0.002	0.95	0.08	0.06	0.09	0.03	0.01	0.87	0.03	0.50								
Creatinine	-0.05	0.19	-0.03	0.45	-0.05	0.24	-0.02	0.62	0.02	0.67	0.02	0.55	-0.05	0.26	-0.04	0.35								
Liver function tests																								
ALT					0.54	<0.0001	0.41	<0.0001	0.52	<0.0001	0.53	<0.0001	0.11	0.006	0.06	0.13								
GGT	0.54	<0.0001	0.42	<0.0001					0.11	0.008	0.06	0.13	0.15	0.0002	0.10	0.02								
AST	0.52	<0.0001	0.53	<0.0001	0.11	0.01	0.06	0.13					-0.005	0.91	-0.02	0.69								

* Values of leptin were logarithmically transformed for analysis.

Model 1: Pearson correlation coefficients and the probabilities associated with this statistics.

Model 2: Pearson partial correlation coefficients were obtained after controlling for the effects of age, smoking status, activity, BMI, body fat percentage, and WHR.

P<0.0125 was considered statistically significant based on Bonferroni correction testing four dependent hypotheses at same time on one set of data.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BMR, basal metabolic rate; DBP, Diastolic blood pressure; GGT, gamma-glutamyl transferase; HDL, High-density lipoprotein; HOMA-IR, homeostasis model of assessment-insulin resistance; LBP, leptin-binding protein; LDL, Low-density lipoprotein; SBP, Systolic blood pressure; WHR, waist-to-hip ratio.

Table 3

Baseline and follow-up characteristics of participants in the prospective study.

Variables	At baseline (n= 93)	At follow-up (n= 93)	P*
Age (yr)	18.2±0.01		
Activity (hr/week)	11.3±1.4		
Anthropometric variables			
Height (cm)	175.0±0.6	175.2±0.6	<.0001
Weight (kg)	68.9±1.3	72.9±1.3	<.0001
BMI (kg/m ²)	22.5±0.4	23.7±0.4	<.0001
Total body fat (%)	12.8±0.6	15.6±0.6	<.0001
Fat mass (kg)	9.5±0.7	12.1±0.8	<.0001
Fat-free mass (kg)	59.4±0.7	60.9±0.7	<.0001
Waist circumference (cm)	79.1±1.0	83.8±1.0	<.0001
Hip circumference (cm)	95.7±0.8	97.1±0.8	0.0005
Waist-to-hip ratio	0.82±0.004	0.86±0.004	<.0001
BMR (kcal/day)	1770±20	1814±20	<.0001
Cardiovascular risk factors			
Heart rate (beats/min)	66.1±0.9	71.6±1.0	<.0001
SBP (mmHg)	106.2±1.1	111.7±1.0	<.0001
DBP (mmHg)	61.7±0.8	71.6±0.7	<.0001
Total cholesterol (mg/dL)	144.2±2.7	159.6±2.8	<.0001
HDL cholesterol (mg/dL)	47.1±0.9	46.0±0.9	0.10
LDL cholesterol (mg/dL)	101.9±2.4	98.4±2.4	0.05
Triglycerides (mg/dL)	58.7±2.3	75.8±4.3	<.0001
Fasting glucose (mg/dL)	78.2±0.7	86.9±1.0	<.0001
Insulin (ng/mL)	7.4±0.3		
HOMA-IR	1.44±0.07		
Leptin (ng/mL)	1.76±0.20		
LBP (ng/mL)	25.0±0.5		
Fetuin-A (ug/mL)	333±8.1		
Uric Acid (ng/dL)	6.6±0.1	6.0±0.1	<.0001
Urea (ng/dL)	35.8±0.7	30.4±0.6	<.0001
Creatinine (ng/dL)	1.05±0.01	1.1±0.01	0.002
Liver Function test			
GGT (U/L)	22.6±0.8	22.2±1.0	0.62
ALT (U/L)	24.1±1.4	21.5±1.3	0.07
AST (U/L)	28.1±1.9	20.3±0.5	0.007
Categorical variables			
Smoking status			
<i>Never</i>	60 (64.5)		
<i>Previous</i>	2 (2.2)		
<i>Current</i>	31 (33.3)		

Variables	At baseline (n= 93)	At follow-up (n= 93)	P*
BMI >25 kg/m ²	17 (18.3)	22 (23.7)	0.35
Waist circumference >94 cm	7 (7.5)	12 (12.9)	0.21
Total cholesterol >200 mg/dL	2 (2.2)	7 (7.5)	0.09
HDL <40 mg/dL	14 (15.1)	22 (23.7)	0.14
LDL >130 mg/dL	12 (12.9)	9 (9.7)	0.49
Dyslipidemia	26 (28.0)	34 (36.6)	0.21

Results are presented as mean±SEM, or as n(%).

* P for difference of follow-up group between baseline and 2-year follow-up, repeated measure analysis were applied for both continuous and categorical variables.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BMR, basal metabolic rate; DBP, Diastolic blood pressure; GGT, gamma-glutamyl transferase; HDL, High-density lipoprotein; HOMA-IR, homeostasis model of assessment-insulin resistance; LBP, leptin-binding protein; LDL, Low-density lipoprotein; SBP, Systolic blood pressure; SE, standard error.

Table 4

Univariable and multivariable linear regression models of liver function tests and fetuin-A in predicting anthropometrics, cardiovascular and metabolic risk factors at 2-year follow-up

	ALT			GGT			AST			Fetuin-A		
	Model 1		Model 2	Model 1		Model 2	Model 1		Model 2	Model 1		Model 2
	β	P	R ²	β	P	R ²	β	P	R ²	β	P	R ²
Anthropometrics												
Height	0.15	0.17	0.02	0.05	0.63	0.00	0.10	0.38	0.009	0.22	0.04	0.050
Weight	0.37	0.0004	0.14	0.44	< 0.0001	0.19	0.08	0.46	0.007	0.15	0.17	0.022
BMI	0.35	0.001	0.13	0.47	< 0.0001	0.22	0.04	0.70	0.002	0.06	0.56	0.004
Total body fat	0.34	0.001	0.12	0.49	< 0.0001	0.24	0.09	0.43	0.008	0.02	0.83	0.001
Fat mass	0.35	0.001	0.12	0.48	< 0.0001	0.23	0.08	0.45	0.007	0.05	0.66	0.002
Fat free Mass	0.34	0.001	0.12	0.02	0.76	0.62	0.06	0.56	0.004	-0.05	0.48	0.62
Waist circumference	0.36	0.001	0.13	0.52	< 0.0001	0.27	0.03	0.81	0.001	0.11	0.33	0.011
Hip circumference	0.33	0.002	0.11	0.43	< 0.0001	0.19	0.07	0.53	0.005	0.10	0.36	0.010
Waist-to-hip ratio	0.30	0.01	0.09	0.51	< 0.0001	0.26	-0.06	0.60	0.596	0.03	0.43	0.007
BMR	0.37	0.001	0.13	0.02	0.80	0.74	0.09	0.42	0.008	-0.03	0.64	0.74
Cardiovascular risk factors												
Heart rate	0.23	0.03	0.05	0.21	0.09	0.08	0.25	0.02	0.06	0.24	0.08	0.09
SBP	0.07	0.50	0.01	-0.10	0.38	0.23	0.17	0.114	0.03	0.06	0.63	0.23
DBP	0.16	0.15	0.02	0.04	0.72	0.21	0.06	0.55	0.00	-0.04	0.76	0.21
Total Cholesterol	0.22	0.04	0.05	0.23	0.06	0.10	0.27	0.01	0.07	0.29	0.03	0.12
HDL	-0.04	0.71	0.00	-0.04	0.77	0.03	-0.02	0.87	0.00	-0.04	0.78	0.03
LDL	0.27	0.01	0.07	0.29	0.02	0.12	0.32	0.003	0.10	0.39	0.003	0.16
Triglycerides	0.02	0.86	0.00	-0.03	0.80	0.11	0.00	0.99	0.00	-0.10	0.43	0.11
Hormonal and metabolic variables												
Fasting glucose	0.06	0.58	0.00	0.00	0.97	0.12	0.06	0.61	0.003	0.04	0.78	0.12
Uric Acid	0.02	0.87	0.00	-0.15	0.18	0.22	0.10	0.36	0.01	-0.05	0.69	0.20
Urea	0.04	0.69	0.00	0.07	0.55	0.08	-0.08	0.48	0.006	-0.04	0.79	0.07
Creatinine	-0.09	0.42	0.01	-0.06	0.64	0.08	-0.21	0.05	0.05	-0.16	0.24	0.09

Model 1: unadjusted model.

Model 2: adjusted for age, smoking status, activity, BMI, body fat percentage, and waist to hip ratio.

β denotes the adjusted regression coefficient.

$P < 0.0125$ was considered statistically significant based on Bonferroni correction testing four dependent hypotheses at the same time using one set of data.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BMR, basal metabolic rate; DBP, Diastolic blood pressure; GGT, gamma-glutamyl transaminase; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; SBP, Systolic blood pressure.